Key Takeaways Current GLP-1 weight-loss meds need to be taken as injections, but new trial results suggest a GLP-1 in pill ...

Using a strategic mix of plant-based foods, the Portfolio Diet can lower LDL cholesterol nearly as much as some prescription ...

Oral weight-loss pills will be replacing GLP-1 shots by March 2026, Medicare and Medicaid Services Administrator Dr. Mehmet Oz predicted on Monday. Oz made the statement during a Monday morning ...

A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly injection has been shown to be as effective as Mounjaro – but patients ...

Over 24% of Indian adults across all states are now considered overweight or obese with more than 12.5 million children under 5 battling obesity ...

Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global demand ahead of a potential launch next year. “We’ve already made, actually, ...

EAST PROVIDENCE, R.I. (WPRI) — A weight loss pill may become available by the end of this year or early in 2026. Dr. Ashish Jha, dean of Brown University’s School of Public Health, joined 12 News at 4 ...

LAS VEGAS, NV, October 16, 2025 (EZ Newswire) -- Nonprescription Clinical, opens new tab announced their new three-step, pharmaceutical-grade GLP-1 Weight Loss Toolkit today. The nonprescription ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) currently available for the treatment of obesity are administered as a peptide-based subcutaneous injection, but oral (non-peptide) versions would ...

Ozempic Insulin box and injection pen or insulin cartridge pen for diabetes patients from Novo Nordisk. Blurred pharmacy background. Copenhagen, Denmark - January 29, 2024. A semaglutide pill is ...

Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs. Pfizer on Monday said ...